North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma
Recruiting
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Relapsed/Refractory Multiple Myeloma
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Recruiting
The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
12/17/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
The PROTECT 2 Study : Pressure Injury Treatment by Intermittent Electrical Stimulation: A Randomized, Controlled Trial
Recruiting
Multicentered randomized controlled study with adaptive design to evaluate if Intermittent Electrical Stimulation (IES) decreases progression and facilitates healing of pressure injuries for patients with, sacral / ischial pressure injuries.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Wake Forest Unverisity, Winston-Salem, North Carolina
Conditions: Stage 1 Pressure Ulcer, Stage 2 Pressure Ulcer
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
Recruiting
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a topical hemostatic agent in surgical wounds, and when used as a colon cleanser for endoscopic surgical procedures. However, PEG fusion has not been rigorously tested as a safe reagen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/17/2024
Locations: OrthoCarolina, Charlotte, North Carolina
Conditions: Peripheral Nerve Injuries
STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad Tendon
Recruiting
Anterior cruciate ligament (ACL) rupture is one of the most common musculoskeletal injuries in young individuals, particularly those that are active in sports. Up to 30% of individuals under the age of 20 years suffer a re-injury to the reconstructed ACL. Revision ACLR has been associated with degeneration of the articular cartilage and increased rates of meniscal tears, increasing the risk of post-traumatic osteoarthritis (PTOA), additional surgical procedures, reduced physical function and qua... Read More
Gender:
ALL
Ages:
Between 14 years and 25 years
Trial Updated:
12/17/2024
Locations: Wake Forest University School of Medicine, Winston-Salem, North Carolina
Conditions: Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
Recruiting
The goal of this clinical trial is to learn whether IBD patients have better disease outcomes and feel more empowered to manage their condition if they have access to text messaging with their clinical team and if their symptoms are more regularly monitored through text-based surveys. Researchers will compare participants who have access to text-based monitoring, communication and education to participants who have access to text-based education alone. Researchers will also examine if different... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
12/16/2024
Locations: UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
Microneedling vs Dermabrasion for Early Facial Scar Resurfacing
Recruiting
This study aims to determine whether microneedling or dermabrasion in the early post-operative period is superior in improving the appearance of surgical scars on the face.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Scar
Letrozole in Uterine Leiomyosarcoma
Recruiting
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: East Carolina University Health Medical Center, Greenville, North Carolina
Conditions: Uterine Leiomyosarcoma
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Cone Health Cancer Center at Alamance Regional, Hematology/Oncology, Greensboro, North Carolina
Conditions: Breast Cancer
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Recruiting
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Novant Health Cancer Institute, Charlotte, North Carolina
Conditions: Cervical Cancer
NOninVasive Intracranial PrEssure from Transcranial DoppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting
This is an observational study in neurocritical care units at University of California San Francisco Medical Center (UCSFMC), Zuckerberg San Francisco General Hospital (ZSFGH), UC Davis, and Emory University. In this study, the investigators will primarily use the monitor mode of the Transcranial Doppler (TCD, non-invasive FDA approved device) to record cerebral blood flow velocity (CBFV) signals from the Middle Cerebral Artery and Internal Carotid Artery. TCD data and intracranial pressure (ICP... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Duke University, Durham, North Carolina
Conditions: Traumatic Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Liver Failure, Ischemic Stroke